VANCOUVER, BC, Sept. 19, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of its previously announced non-brokered private placement (the “Private Placement”). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units (“Units”) at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August 26, 2022, the Company raised total aggregate gross proceeds of $335,000. Each Unit consists of one common share (a “Common Share”) and one whole Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.20 for a period of 48 months. There were finder’s fees totalling $6,400 paid in connection with the Final Tranche.
All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for working capital.
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, CEO
+1 646 452 7054
Cautionary Statements Regarding Forward Looking Information
This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the second tranche of th Private Placement, the use of proceeds of the Private Placement and the overall development of BioVaxys’ vaccines and diagnostic technologies. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in locating suitable purchasers for Private Placement and in developing and testing vaccines and diagnostic tools, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys’ vaccines and diagnostic tools will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biovaxys-closes-final-tranche-of-non-brokered-private-placement-301627761.html
SOURCE BioVaxys Technology Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/19/c4481.html
Buenos Aires-based FilmSharks subsidiary The Remake Company has closed a remake deal with Italy’s Marco Belardi and his new label Bamboo Prod. for Ariel Winograd’s latest film “Today We Fix the World” (“Hoy se Arregla el Mundo”). Produced by powerhouse shingle Patagonik, the family dramedy was picked up by Netflix for several key territories after […]
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy vo
What happened Ford (NYSE: F) shareholders didn't wake up to good news Tuesday. The company put out an earnings warning and made clear that it is still struggling to navigate supply chain challenges. The stock reacted with more than a 10% drop in morning trading.
The ‘70s are coming back in a big way, and while that’s not so bad in fashion or in music, it’s safe to say that no one really wants that ‘70s economy back. That was the decade that brought stagflation, a nasty mix of high inflation, increasing unemployment, and stagnant job growth. Economists had long thought that combo impossible, but the economic mismanagement of the Carter Administration proved them wrong. At least one top economist, Mohamed El-Erian from Allianz, sees a stagflationary perio
Yahoo Finance Live’s Julie Hyman breaks down how stocks are trading as Fed meeting gets underway.
In this article, we discuss the 10 long-term stocks to buy according to billionaire Mario Gabelli. If you want to read about some more stocks in the Gabelli portfolio, go directly to 5 Long-Term Stocks to Buy According to Billionaire Mario Gabelli. The investing acumen of legendary value investors like Mario Gabelli of GAMCO Investors […]
You have to applaud Cathie Wood's all-weather transparency. Wood kicked off the new trading week by adding to her existing stakes in Adobe (NASDAQ: ADBE), Velo3D (NYSE: VLD), and General Motors (NYSE: GM) on Monday. It's great to see Wood go shopping, but the market doesn't think it's all that great when her investments are the ones doing the shopping.
Savvy investors could use the temporary decline in an upward-trending oil refining market to buy stocks like PBF, VLO and PSX at a discount.
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Does the September share price for Occidental Petroleum Corporation ( NYSE:OXY ) reflect what it's really worth? Today…
Since inflation data for August came in hotter than expected last week, investors have been on edge. Despite the pain, the worst still may be to come, with the Federal Reserve's September meeting kicking off today and wrapping up tomorrow. Here's how the Fed could crush the stock market tomorrow and also why you shouldn't panic.
Ignore Buffett's wisdom? Maybe just this once.
This passive-income powerhouse offers a nearly 15% yield and is slated to split its shares in less than a week.
Micron (MU) closed the most recent trading day at $52.10, moving -1.42% from the previous trading session.
This diverse basket of industrial companies has served as a reliable source of passive income for decades.
Advanced Micro Devices stock is down about 50% from its highs, but its business hums along. Let's look at where support may come into play.
The company has lost more than 92% of its market value in the last 12 months
Tellurian cites 'uncertain conditions in the high-yield market' as the reason for the withdrawal.
Warren Pies, co-founder and strategist at 3Fourteen Research, identifies is the single-best bad news fighting asset around right now.
What’s going on in the markets lately? Since the start of this year, we’ve seen a prolonged bearish trend, and now a cycle of high volatility. Investors can be forgiven for feeling some confusion, or even some whiplash, in trying to follow the rapid ups and downs of recent weeks. One important fact does stand out, however. Over the past three months, since mid-June, we’ve see rallies and dips – but the markets have not seriously challenged that mid-June low point. Examining the situation from re